Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

ABSTRACT: Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

PROVIDER: PRJNA330817 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

Project description:Comparison of single-cell transcriptomic profiles of cell lines obtained from the primary and metastatic tumor from a single patient.

2017-07-12 | GSE84323 | GEO

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-07-21 | GSE84676 | GEO

Phenotype-driven precision oncology in patient-derived tumor models predict therapeutic response in squamous cell carcinoma [expression]

Project description:Gene expression analysis of patient metastatic tumor derived cell lines.

2017-07-21 | GSE100123 | GEO

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Project description:Precision oncology has made significant advances in the last few years, mainly by targeting actionable mutations in cancer driver genes. However, the proportion of patients whose tumors can be targeted therapeutically remains limited. Recent studies have begun to explore the benefit of analyzing tumor transcriptomics data to guide patient treatment, raising the need for new approaches for systematically accomplishing that. Here we show that computationally derived genetic interactions can successfully predict patient response.

2021-02-11 | GSE166449 | GEO

CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

Project description:CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

| PRJNA574689 | ENA

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

2022-09-01 | GSE184242 | GEO

The OncoLoop Network-based Precision Oncology Framework

Project description:We introduce OncoLoop, a highly-generalizable, precision medicine framework to triangulate between available mouse models, human tumors, and large-scale drug perturbational assays with in vivo validation to predict personalized treatment

2022-10-31 | GSE186566 | GEO

A Single-Cell Tumor Immune Atlas for Precision Oncology

Project description:The tumor immune microenvironment is a main contributor to cancer progression and a promising therapeutic target for oncology. However, immune microenvironments vary profoundly between patients and biomarkers for prognosis and treatment response lack precision. A comprehensive compendium of tumor immune cells is required to pinpoint predictive cellular states and their spatial localization. We generated a single-cell resolved tumor immune cell atlas, jointly analyzing >500,000 cells from 217 patients and 13 cancer types, providing the basis for a patient stratification based on immune cell compositions. Projecting immune cells from external tumors onto the atlas facilitated an automated cell annotation system for a harmonized interpretation. To enable in situ mapping of immune populations for digital pathology, we developed SPOTlight, a computational tool that identified striking spatial immune cell patterns in tumor sections. We expect the atlas, together with our versatile toolbox for precision oncology, to advance currently applied stratification strategies for prognosis and immuno-therapy response.

2020-10-27 | GSE158803 | GEO

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Project description:Synthetic lethality-mediated precision oncology via the tumor transcriptome

| PRJNA700986 | ENA

A Single-Cell Tumor Immune Atlas for Precision Oncology

Project description:A Single-Cell Tumor Immune Atlas for Precision Oncology

| PRJNA666613 | ENA